摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3aR,4S,5R,6aS)-4-(叔-丁基二苯基硅烷基氧基)甲基-5-羟基-六氢-2H-环戊[b]呋喃-2-酮 | 84786-80-1

中文名称
(3aR,4S,5R,6aS)-4-(叔-丁基二苯基硅烷基氧基)甲基-5-羟基-六氢-2H-环戊[b]呋喃-2-酮
中文别名
——
英文名称
(3aR,4S,5R,6aS)-hexahydro-5-hydroxy-4-[(tert-butyldiphenylsilyloxy)methyl]-2H-cyclopenta[b]furan-2-one
英文别名
(3aR,4S,5R,6aS)-4-[(t-butyldiphenylsiloxy)methyl]-5-hydroxyhexahydro-2H-cyclopenta[b]furan-2-one;(3aR,4S,5R,6aS)-4-(tert-Butyldiphenylsilyloxy)methyl-5-hydroxy-hexahydro-2H-cyclopenta[b]furan-2-one;(3aR,4S,5R,6aS)-4-[[tert-butyl(diphenyl)silyl]oxymethyl]-5-hydroxy-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-one
(3aR,4S,5R,6aS)-4-(叔-丁基二苯基硅烷基氧基)甲基-5-羟基-六氢-2H-环戊[b]呋喃-2-酮化学式
CAS
84786-80-1
化学式
C24H30O4Si
mdl
——
分子量
410.585
InChiKey
JFKQASGNSCLFLO-YSFYHYPLSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    90-91 °C
  • 沸点:
    520.7±46.0 °C(Predicted)
  • 密度:
    1.16±0.1 g/cm3(Predicted)
  • 溶解度:
    可溶于丙酮、氯仿、二氯甲烷、乙酸乙酯、甲醇

计算性质

  • 辛醇/水分配系数(LogP):
    2.88
  • 重原子数:
    29
  • 可旋转键数:
    6
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.46
  • 拓扑面积:
    55.8
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • 15-ketal postaglandins for the treatment of glaucoma or ocular hypertension
    申请人:Alcon Laboratories, Inc.
    公开号:US06353014B1
    公开(公告)日:2002-03-05
    A method of treating glaucoma or ocular hypertension in a patient, which comprises administering to the patient a pharmaceutically effective amount of a compound of formula I:
    一种治疗青光眼或眼压高的方法,包括向患者施用化合物I的药效量。
  • 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension
    申请人:Alcon Laboratories, Inc.
    公开号:US06353000B1
    公开(公告)日:2002-03-05
    A method of treating glaucoma or ocular hypertension in a patient, which comprises administering to the patient a pharmaceutically effective amount of a compound of formula I:
    一种治疗青光眼或眼压增高的方法,包括向患者施用公式I的化合物的药物有效量。
  • Synthesis of (1R, 4S, 5R)-9-(4,5-bishydroxy-methylcyclopent-2-en-1-yl)-9H-adenine [(-)-BCA] and selective inhibition of human immunodeficiency virus
    作者:Nobuya Katagiri、Akemi Toyota、Takuya Shiraishi、Hiroshi Sato、Chikara Kaneko
    DOI:10.1016/s0040-4039(00)92675-3
    日期:1992.6
    (1R,4S,5R)-9-(4,5-Bishydroxymethylcyclopent-2-en-1-yl)-9H-adenine [(-)-BCA] has been synthesized from (-)-Corey lactone in 11 steps and shown to have potent and selective effects against human immunodeficiency virus type 1. The result demonstrated that the potent-HIV activity of racemic BCA obtained in our previous work is expressed solely by the (1R,4S,5R)-(-)-isomer.
    (1R,4S,5R)-9-(4,5-双羟甲基环戊-2-烯-1-基)-9H-腺嘌呤 [(-)-BCA] 从 (-)-科里内酯出发,经过11步反应合成,并显示出对人类免疫缺陷病毒1型的强效和选择性抑制作用。结果显示,在我们之前工作中获得的消旋BCA的强效抗HIV活性仅由 (1R,4S,5R)-(-)-异构体表达。
  • Synthesis and evaluation of 2,3-dinorprostaglandins: Dinor-PGD1 and 13-epi-dinor-PGD1 are peroxisome proliferator-activated receptor α/γ dual agonists
    作者:Ayato Sato、Kosuke Dodo、Makoto Makishima、Yuichi Hashimoto、Mikiko Sodeoka
    DOI:10.1016/j.bmcl.2013.03.024
    日期:2013.5
    2,3-Dinorprostaglandins (dinor-PGs) have been regarded as beta-oxidation products of arachidonic-acid-derived prostaglandins, but their biological activities in mammalian cells remain unclear. On the other hand, C18 polyunsaturated fatty acids (PUFAs), such as gamma-linolenic acid (GLA), have various biological activities, and dinor-PGs are speculated to be biosynthesized from GLA. Here, we synthesized dinor-PGs that may possibly be derived from GLA and examined their activities towards peroxisome proliferator-activated receptors (PPARs). Dinor-PGD(1) (1) and its epimer 13-epi-dinor-PGD(1) (epi-1) were found to be dual agonists for PPAR alpha/gamma, whereas PGD(2) derived from arachidonic acid is selective for PPAR gamma. Thus, GLA-derived dinor-PGs may have unique biological roles. (C) 2013 Elsevier Ltd. All rights reserved.
  • Griffin, Brenda W.; Klimko, Peter; Crider, Julie Y., Journal of Pharmacology and Experimental Therapeutics, 1999, vol. 290, # 3, p. 1278 - 1284
    作者:Griffin, Brenda W.、Klimko, Peter、Crider, Julie Y.、Sharif, Najam A.
    DOI:——
    日期:——
查看更多